Rimini BidCo Announces Floating Rate Sustainability-linked Senior Secured Notes Offering
Rimini BidCo S.p.A. (the “Company”), an entity controlled by funds affiliated with Apollo Global Management, Inc., announces its intention to issue and sell €445 million Floating Rate Sustainability-Linked Senior Secured Notes due 2026 (the “Notes”) in an offering (the “Offering”) that will be exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”).
The Company expects to use the gross proceeds of the Offering to (i) repay certain outstanding borrowings of Reno de Medici S.p.A. (“RdM”) and its subsidiaries, (ii) repay outstanding borrowings incurred by the Company in connection with the acquisition of RdM and (iii) pay certain fees and expenses relating to the acquisition of RdM.
The Company reserves the right to determine whether to proceed with the Offering based on market conditions.
The Notes are being offered only to persons reasonably believed to be (i) qualified institutional buyers within the meaning of Rule 144A under the Securities Act and (ii) non-U.S. investors pursuant to Regulation S under the Securities Act. The Notes will not be registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent a valid registration statement or an applicable exemption from registration requirements or a transaction not subject to the registration requirements of the Securities Act or any state securities laws.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.
MiFID II professionals/ECPs-only/No PRIIPs KID – Manufacturer target market (MIFID II product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs key information document (KID) has been prepared as not available to retail in EEA and the UK.
Forward-Looking Statements
This communication and other written or oral statements made by or on behalf of the Company contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are made under the “safe harbor” provisions of The Private Securities Litigation Reform Act of 1995. In particular, statements using words such as “may,” “seek,” “will,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “foresee”, “might”, “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Forward-looking statements reflect the Company’s current views, plans or expectations with respect to future events and financial performance. They are inherently subject to significant business, economic, competitive and other risks, uncertainties and contingencies. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by the Company or any other person that current plans or expectations will be achieved. Accordingly, you should not place undue reliance on any forward-looking statement. Forward-looking statement speak only as of the date on which they are made, and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as otherwise required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123005699/en/
Contact information
For investor inquiries regarding Apollo, please contact:
Noah Gunn
Global Head of Investor Relations
(212) 822-0540
IR@apollo.com
For media inquiries please contact:
Joanna Rose
Global Head of Corporate Communications
Apollo Global Management, Inc.
(212) 822-0491
Communications@apollo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gulf Oil Selects DataXstream’s OMS+ Portal to Power LATAM Digital Transformation9.12.2025 15:33:00 EET | Press release
DataXstream LLC, an SAP® Endorsed App partner developing innovative solutions for SAP sales and distribution, today announced that Gulf Oil, a globally recognized lubricant company with operations in more than 25 countries, has selected OMS+ Portal to modernize and unify the company’s customer-facing sales platform across Latin America. The project is part of a broader initiative to streamline operations, enhance scalability and deliver a seamless buying experience that is fully integrated with SAP S/4HANA. As Gulf Oil continues its footprint across LATAM, the company needed a solution that would not only elevate the customer experience, but also provide the flexibility and performance needed to scale. OMS+ Portal will serve as the central platform for Gulf’s distributor network, offering a unified, SAP-embedded environment for self-service ordering and real-time collaboration. “We chose OMS+ Portal because it is a certified SAP partner that will help us to scale the customer portal ac
Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy9.12.2025 15:05:00 EET | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This partnership is the latest in a series of public-private partnerships Guardant Health has formed with top-tier European academic and research hospitals that embed its groundbreaking technology with existing care pathways to expand access to more cancer patients. Policlinico Gemelli will offer on-site liquid biopsy testing based on Guardant360® CDx technology. The collaboration expands access to precision oncology diagnostics and supports both routine care and clinical research. FPG 360 is one of the first dedicated liquid biopsy testing facilities in Italy housed within a hospital system. Policlinico Gemelli, one of Italy's largest and most renowned hospitals, serves thousands of cancer patients each year at its com
Avia Expands to Europe with New German Subsidiary9.12.2025 15:00:00 EET | Press release
AviaGames, a leading global mobile skill-based gaming platform, today announced the establishment of a new subsidiary in Germany. Games industry veteran Michelle Zou has been appointed to head the new entity, overseeing market expansion and investment initiatives across Europe. This move marks a significant milestone in AviaGames’ global growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209920028/en/ Games industry veteran Michelle Zou has been appointed to head the AviaGames German subsidiary, overseeing market expansion and investment initiatives across Europe. AviaGames has rapidly emerged as one of the most prominent interactive entertainment companies worldwide, with a global user base of tens of millions of players across North America, and Europe, spanning North America and beyond. The company is especially recognized for its popularity among female players and for delivering high-quality, skill-based
ExaGrid Wins 3 New Industry Awards at the MSP Channel Awards9.12.2025 15:00:00 EET | Press release
ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that the company was honored with three awards during the 1st annual MSP Channel Awards ceremony, held in London on December 3, 2025, including: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209577454/en/ Photo courtesy of MSP Channel Awards. Backup & DR Innovation of the Year Storage Hardware Innovation of the Year Storage Vendor of the Year Many Managed Service Providers (MSPs) use ExaGrid Tiered Backup Storage to offer their customers Backup as a Service (BaaS), Disaster Recovery as a Service (DRaaS), and IT Data Center Outsourcing. In 2025, ExaGrid released new features that help MSPs track their customers’ data usage and separately provide the ability to restore an
Aqemia to Attend the 44th Annual J.P. Morgan Healthcare Conference 20269.12.2025 15:00:00 EET | Press release
Aqemia, a drug invention company combining generative AI and quantum-inspired physics, announces it will attend and hold 1x1 meetings at the 44th Annual J.P. Morgan Healthcare Conference, taking place at The Westin St. Francis in San Francisco from January 12 to 15, 2026. Aqemia will be represented by Maximilien Levesque, CEO and co-founder, Emmanuelle Martiano, COO and co-founder, and Théa Vu-Bignand, VP Finance. Powered by QEMI, its proprietary physics-based generative AI engine for therapeutic molecule invention, Aqemia designs novel drug candidates in a repeatable, efficient, and scalable way. The company focuses on advancing its internal preclinical pipeline while establishing partnerships that validate its platform and scientific differentiation, with the ambition to accelerate the delivery of new therapies in areas of high unmet medical need. About Aqemia Aqemia is a drug invention company dedicated to creating novel molecules to address unmet medical needs. Its proprietary QEMI
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
